Wednesday, July 8, 2026
🇺🇸 FDA

biotech · Lung Cancer · Non-small Cell Lung Cancer (NSCLC) · RVMD

Revolution Medicines

Revolution Medicines clinical programs — 26 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
700 Saginaw Dr., Redwood City, California 94063, US HQ
2014 Founded
1,050 Employees
Public company Type
RVMD · NYSE Ticker
Company details
Status
Public
HQ
700 Saginaw Dr., Redwood City, California 94063, US
Founded
2014
Employees
1,050
Programs
26
Drugs
28
Patents
36
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Revolution Medicines projects

26 ClinicalTrials.gov programs sponsored by Revolution Medicines.

Revolution Medicines has 26 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

26 programs

Clinical programs

  1. DARAXONRASIB (RMC-6236), DARAXONRASIB (RMC-6236)

    Revolution Medicines

    Resected Pancreatic Ductal Adenocarcinoma (PDAC)

    phase 3 small molecule active

    1 trial

  2. RMC-6236

    Revolution Medicines

    Pancreatic Cancer

    phase 3 small molecule active

    1 trial

  3. RMC-6236-301

    Revolution Medicines

    non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  4. RMC-6236-302

    Revolution Medicines

    Metastatic Pancreatic Ductal Adenocarcinoma

    phase 3 small molecule active

    1 trial

  5. daraxonrasib

    Revolution Medicines

    Pancreatic Cancer

    phase 3 small molecule active

    2 trials

  6. daraxonrasib

    Revolution Medicines

    NSCLC (Non-small Cell Lung Cancer)

    phase 3 small molecule active

    1 trial

  7. Daraxonrasib

    Revolution Medicines

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  8. Elironrasib

    Revolution Medicines

    Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  9. RMC-4630

    Revolution Medicines

    Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  10. RMC-4630

    Revolution Medicines

    Solid Tumor

    phase 2 small molecule completed

    1 trial

  11. RMC-6236

    Revolution Medicines

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  12. RMC-6236

    Revolution Medicines

    Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  13. RMC-9805

    Revolution Medicines

    Lung Cancer

    phase 2 small molecule active

    1 trial

  14. RMC-LUNG-101C

    Revolution Medicines

    Lung Cancer

    phase 2 small molecule active

    1 trial

  15. TNG462

    Revolution Medicines

    PDAC

    phase 2 small molecule active

    1 trial

  16. Vociprotafib

    Revolution Medicines

    Metastatic Neoplasm

    phase 2 small molecule terminated

    1 trial

  17. RMC-4630

    Revolution Medicines

    Solid Tumors

    phase 1 small molecule active

    1 trial

  18. RMC-5127

    Revolution Medicines

    Non-small Cell Lung Cancer (NSCLC)

    phase 1 small molecule active

    1 trial

  19. RMC-5552

    Revolution Medicines

    Glioblastoma

    phase 1 small molecule terminated

    1 trial

  20. RMC-5552

    Revolution Medicines

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  21. RMC-6291

    Revolution Medicines

    Non-Small Cell Lung Cancer (NSCLC)

    phase 1 small molecule active

    2 trials

  22. RMC-6291-001

    Revolution Medicines

    Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor, Colorectal Cancer (CRC)

    phase 1 other active

    1 trial

  23. RMC-6291-101

    Revolution Medicines

    Participants with Advanced KRASG12C-Mutated Solid Tumors

    phase 1 other active

    1 trial

  24. RMC-9805

    Revolution Medicines

    Non-small Cell Lung Cancer (NSCLC)

    phase 1 small molecule active

    1 trial

  25. RMC-LUNG-101A

    Revolution Medicines

    Lung Cancer

    phase 1 small molecule active

    1 trial

  26. RMC-LUNG-101B

    Revolution Medicines

    Lung Cancer

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Revolution Medicines have?

26 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.